未登录 A Canadian real-world, multi-center, prospective, observational study assessing the treatment duration, the treatment sequence, and the overall survival for patients treated with endocrine therapy ± targeted therapy in HR+HER2-negative advanced breast cancer 加拿大真实世界、多中心、前瞻性、观察性研究评估内分泌治疗 ± 靶向治疗HR HER2-negative晚期乳腺癌患者的治疗持续时间、治疗顺序和总生存率 Doyle, Catherine; Lohmann, Ana Elisa; Iqbal, Nayyer; Henning, Jan-Willem; Kulkarni, Swati; Califaretti, Nadia; Hilton, John; Ferrario, Cristiano; Bouganim, Nathaniel; Mates, Mihaela; Guillemette, Stephanie; Leite, Ricardo; Caron, Marc-Andre; Thireau, Francois; Machado, Andres; Chia, Stephen 分享 收藏
Acquired gene alterations in patients treated with ribociclib plus endocrine therapy or endocrine therapy alone using baseline and end-of-treatment circulating tumor DNA samples in the MONALEESA-2,-3, and-7 trials MONALEESA-2、-3和-7试验中，使用基线和治疗结束时的循环肿瘤DNA样本，评估接受ribociclib联合内分泌治疗或仅接受内分泌治疗患者的获得性基因改变。 Andre, F.; Solovieff, N.; Su, F.; Bardia, A.; Neven, P.; Yap, Y. S.; Tripathy, D.; Lu, Y. -S.; Slamon, D.; Chia, S.; Joshi, M.; Chakravartty, A.; Lteif, A.; Taran, T.; Arteaga, C. L. 分享 收藏
分享 收藏
SGLT2 inhibition improves PI3Kα inhibitor-induced hyperglycemia: findings from preclinical animal models and from patients in the BYLieve and SOLAR-1 trials Borrego, Manuel Ruiz; Lu, Yen-Shen; Reyes-Cosmelli, Felipe; Park, Yeon Hee; Yamashita, Toshinari; Chiu, Joanne; Airoldi, Mario; Turner, Nicholas; Fein, Luis; Ghaznawi, Farhat; Singh, Jyotika; Pantoja, Kristyn; Schnell, Christian; Akdere, Murat; Chia, Stephen 分享 收藏
Ribociclib (RIB) plus nonsteroidal aromatase inhibitor (NSAI) as adjuvant treatment in patients with HR+/HER2-early breast cancer: final invasive disease-free survival (iDFS) analysis from the NATALEE trial Hortobagyi, Gabriel; Stroyakovsky, Daniil; Yardley, Denise; Huang, Chiun-Shen; Fasching, Peter A.; Crown, John; Bardia, Aditya; Chia, Stephen; Im, Seock-Ah; Martin, Miguel; Loi, Sherene; Xu, Binghe; Hurvitz, Sara; Barrios, Carlos; Untch, Michael; Moroose, Rebecca; Visco, Frances; Parnizari, Federico; Ghaznawi, Farhat; Li, Zheng; Waters, Sorcha; Chakravartty, Arunava; Slamon, Dennis 分享 收藏
International Validation of a Staging Model for de novo Metastatic Breast Cancer Plichta, Jennifer; Thomas, Samantha; Siesling, Sabine; de Munck, Linda; Lusque, Amelie; Grinda, Thomas; Gondara, Lovedeep; Chia, Stephen; Cabrera-Galeana, Paula; Reynoso-Noveron, Nancy; Lopez-Tarruella, Sara; Lopez, Isabel Alvarez; Edge, Stephen; Hortobagyi, Gabriel 分享 收藏
分享 收藏
Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer Leon-Ferre, Roberto A.; Jonas, Sarah Flora; Salgado, Roberto; Loi, Sherene; de Jong, Vincent; Carter, Jodi M.; Nielsen, Torsten O.; Leung, Samuel; Riaz, Nazia; Chia, Stephen; Jules-Clement, Gerome; Curigliano, Giuseppe; Criscitiello, Carmen; Cockenpot, Vincent; Lambertini, Matteo; Suman, Vera J.; Linderholm, Barbro; Martens, John W. M.; van Deurzen, Carolien H. M.; Timmermans, A. Mieke; Shimoi, Tatsunori; Yazaki, Shu; Yoshida, Masayuki; Kim, Sung-Bae; Lee, Hee Jin; Dieci, Maria Vittoria; Bataillon, Guillaume; Vincent-Salomon, Anne; Andre, Fabrice; Kok, Marleen; Linn, Sabine C.; Goetz, Matthew P.; Michiels, Stefan 分享 收藏
Health-related quality of life (HRQoL) in the phase III NATALEE study of adjuvant ribociclib (RIB) plus a nonsteroidal aromatase inhibitor (NSAI) vs NSAI alone in patients (pts) with HRD/HER2-early breast cancer (EBC) Fasching, P. A.; Slamon, D.; Nowecki, Z.; Kukielka-Budny, B. D.; Stroyakovskiy, D.; Yardley, D.; Huang, C.; Chan, A.; Chia, S.; Martin, M.; Rugo, H. S.; Loi, S.; Hurvitz, S. A.; Untch, M.; Afenjar, K.; Fresco, R.; Danyliv, A.; Ferrusi, I.; Li, Z.; Hortobagyi, G. N. 分享 收藏
Neratinib plus fulvestrant plus trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial Jhaveri, K.; Eli, L. D.; Wildiers, H.; Hurvitz, S. A.; Guerrero-Zotano, A.; Unni, N.; Brufsky, A.; Park, H.; Waisman, J.; Yang, E. S.; Spanggaard, I.; Reid, S.; Burkard, M. E.; Vinayak, S.; Prat, A.; Arnedos, M.; Bidard, F. -C.; Loi, S.; Crown, J.; Bhave, M.; Piha-Paul, S. A.; Suga, J. M.; Chia, S.; Saura, C.; Garcia-Saenz, J. a.; Gambardella, V.; de Miguel, M. J.; Gal-Yam, E. N.; Raphael, A.; Stemmer, S. M.; Ma, C.; Hanker, A. B.; Ye, D.; Goldman, J. W.; Bose, R.; Peterson, L.; Bell, J. S. K.; Frazier, A.; Diprimeo, D.; Wong, A.; Arteaga, C. L.; Solit, D. B. 分享 收藏
Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2-advanced breast cancer receiving first-line ribociclib plus fulvestrant Neven, P.; Fasching, P. A.; Chia, S.; Jerusalem, G.; De Laurentiis, M.; Im, S. -a.; Petrakova, K.; Bianchi, G. V.; Martin, M.; Nusch, A.; Sonke, G. S.; de la Cruz-merino, L.; Beck, J. T.; Zarate, J. P.; Wang, Y.; Chakravartty, A.; Wang, C.; Slamon, D. J. 分享 收藏
Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR+/HER2-early breast cancer NATALEE的基本原理和试验设计: 在HR /HER2-early乳腺癌患者中，辅助ribociclib加内分泌治疗与单独内分泌治疗的III期试验 Slamon, Dennis J.; Fasching, Peter A.; Hurvitz, Sara; Chia, Stephen; Crown, John; Martin, Miguel; Barrios, Carlos H.; Bardia, Aditya; Im, Seock-Ah; Yardley, Denise A.; Untch, Michael; Huang, Chiun-Sheng; Stroyakovskiy, Daniil; Xu, Binghe; Moroose, Rebecca L.; Loi, Sherene; Visco, Frances; Bee-Munteanu, Valerie; Afenjar, Karen; Fresco, Rodrigo; Taran, Tetiana; Chakravartty, Arunava; Zarate, Juan Pablo; Lteif, Agnes; Hortobagyi, Gabriel N. 分享 收藏
Ten-year update: NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-42 randomized trial: extended letrozole therapy in early-stage breast cancer Mamounas, Eleftherios P.; Bandos, Hanna; Rastogi, Priya; Lembersky, Barry C.; Jeong, Jong-Hyeon; Geyer Jr, Charles E.; Fehrenbacher, Louis; Chia, Stephen K.; Brufsky, Adam M.; Walshe, Janice M.; Soori, Gamini S.; Dakhil, Shaker R.; Wade III, James L.; McCarron, Edward C.; Swain, Sandra M.; Wolmark, Norman 分享 收藏
Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial 以曲妥珠单抗为基础的HER2-positive乳腺癌辅助治疗后neratinib的总生存期 (ExteNET): 一项随机、双盲、安慰剂对照的3期试验 Holmes, Frankie A.; Moy, Beverly; Delaloge, Suzette; Chia, Stephen K. L.; Ejlertsen, Bent; Mansi, Janine; Iwata, Hiroji; Gnant, Michael; Buyse, Marc; Barrios, Carlos H.; Silovski, Tajana; Separovic, Robert; Bashford, Anna; Zotano, Angel Guerrero; Denduluri, Neelima; Patt, Debra; Gokmen, Erhan; Gore, Ira; Ii, John W. Smith; Loibl, Sibylle; Masuda, Norikazu; Tomasevic, Zorica; Petrakova, Katarina; DiPrimeo, Daniel; Wong, Alvin; Martin, Miguel; Chan, Arlene 分享 收藏
Design of SERENA-6, a phase III switching trial of camizestrant in ESR1-mutant breast cancer during first-line treatment Turner, Nicholas; Huang-Bartlett, Cynthia; Kalinsky, Kevin; Cristofanilli, Massimo; Bianchini, Giampaolo; Chia, Stephen; Iwata, Hiroji; Janni, Wolfgang; Ma, Cynthia X.; Mayer, Erica L.; Park, Yeon Hee; Fox, Steven; Liu, Xiaochun; McClain, Sasha; Bidard, Francois-Clement 分享 收藏
Genomic characterisation of hormone receptor-positive breast cancer arising in very young women Luen, S. J.; Viale, G.; Nik-Zainal, S.; Savas, P.; Kammler, R.; Dell'Orto, P.; Biasi, O.; Degasperi, A.; Brown, L. C.; Lang, I.; MacGrogan, G.; Tondini, C.; Bellet, M.; Villa, F.; Bernardo, A.; Ciruelos, E.; Karlsson, P.; Neven, P.; Climent, M.; Mueller, B.; Jochum, W.; Bonnefoi, H.; Martino, S.; Davidson, N. E.; Geyer, C.; Chia, S. K.; Ingle, J. N.; Coleman, R.; Solbach, C.; Thurlimann, B.; Colleoni, M.; Coates, A. S.; Goldhirsch, A.; Fleming, G. F.; Francis, P. A.; Speed, T. P.; Regan, M. M.; Loi, S. 分享 收藏
Identification of mechanisms of acquired resistance to ribociclib plus endocrine therapy using baseline and end-of-treatment circulating tumor DNA samples in the MONALEESA-2,-3, and-7 trials Andre, Fabrice; Solovieff, Nadia; Su, Faye; Bardia, Aditya; Neven, Patrick; Yap, Yoon-Sim; Tripathy, Debu; Lu, Yen-Shen; Slamon, Dennis; Chia, Stephen K.; Joshi, Mukta; Chakravartty, Arunava; Lteif, Agnes; Taran, Tetiana; Arteaga, Carlos 分享 收藏
Long-Term and Very-Long-Term Disease Control in Patients From BYLieve Study Cohort A With PIK3CA-Mutant, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, Advanced Breast Cancer Rugo, Hope; Chia, Stephen K.; Cortes, Javier; Curigliano, Giuseppe; Neven, Patrick; Dent, Rebecca; Tolaney, Sara; Ciruelos, Eva; Park, Yeon H.; Roux, Estelle; Chattar, Yogesh; Patino, Heather; Akdere, Murat; Juric, Dejan 分享 收藏
Comparing the efficacy of aromatase inhibitors vs tamoxifen in hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: a systematic review and trial-level meta-analysis Janni, Wolfgang; Untch, Michael; Harbeck, Nadia; Gilgorov, Joseph; Jacot, William; Chia, Stephen K.; Boileau, Jean-Francois; Haftchenary, Sina; Gupta, Rhea; Mishra, Namita; Pathak, Purnima; Curigliano, Giuseppe 分享 收藏
CCTG MA40: DOUBLE-BLIND PLACEBO CONTROLLED PHASE III TRIAL OF FULVESTRANT AND IPATASERTIB FOR ADVANCED HER-2 NEGATIVE AND ESTROGEN RECEPTOR POSITIVE (ER plus ) BREAST CANCER POST FIRST LINE CDK 4/6 AND AROMATASE INHIBITOR THERAPY (FINER) Chia, Stephen K.; Cescon, David W.; Redfern, Andrew D.; Rodin, Danielle; Simmons, Christine; Ayoub, Jean-Pierre; Chalchal, Haji Ibrahim; Rayson, Daniel; Rushton-Marovac, Moira; Hay, Tracey; Gallinaro, Lisa; Chen, Bingshu; Parulekar, Wendy 分享 收藏
.png){kind=icon}
.png){kind=icon}
.png)
OAAI
.png){kind=icon}
分享.png){kind=icon}
收藏.png)
ANNALS OF ONCOLOGY